To hear about similar clinical trials, please enter your email below
Trial Title:
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
NCT ID:
NCT06238284
Condition:
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
HER2 Expression
Conditions: Official terms:
Ovarian Neoplasms
Uterine Cervical Neoplasms
Endometrial Neoplasms
Conditions: Keywords:
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
HER2 Expression
Therapeutic efficacy
Prognosis
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
no intervention
Description:
Since it is a retrospective study, no intervention is needed.
Arm group label:
Cervical Cancer Group
Arm group label:
Endometrial Cancer Group
Arm group label:
Ovarian Cancer Group
Summary:
This study aims to retrospectively analyze the HER2 expression of gynecological malignant
tumors in Chongqing by immunohistochemical detection, and explore the correlation between
HER2 level, therapy response and prognosis based on patient clinical information.
Criteria for eligibility:
Study pop:
Women with cervical adenocarcinoma (including carcinosarcoma), adenocarcinoma of uterus
(including carcinosarcoma), or ovarian cancer, etc.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients with primary gynecological malignant tumor confirmed by histopathology
- Women aged 18-75
- The expected survival time is greater than 12 weeks
- KPS > 60, ECOG score is 0-2
- All subjects voluntarily joined this study with informed consents, and had good
compliance of follow-up
Exclusion Criteria:
- Pregnant and lactating women
- Suffering from other malignant tumors in the past 5 years
- Patients who are not suitable for this study according to the investigator's
judgment
Gender:
Female
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Start date:
January 26, 2024
Completion date:
May 31, 2024
Lead sponsor:
Agency:
Chongqing University Cancer Hospital
Agency class:
Other
Source:
Chongqing University Cancer Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06238284
